CRF awards four global grants to advance CHM research toward new clinical trial endpoints and therapeutic approaches—driving progress toward treatments.

At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...

Of the phase III trials that planned to report QoL outcomes, nearly 40% never did ...

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...

Abrocitinib shows sustained improvement in atopic dermatitis symptoms over two years with an acceptable safety profile.

FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...

Supervised HIIT and CME combined with resistance training significantly improved physical function in older patients with HIV.

Phoenix Ortho integrates Prescribe FIT into Phoenix Go, enabling one-tap lifestyle health & RPM enrollment and ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Investigators evaluated the long-term impact of taxane chemotherapy on patient-reported neuropathy, balance problems, and falls among older breast cancer survivors.